Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

被引：0

作者：

Tomokazu Tamura

Takashi Irie

Sayaka Deguchi

Hisano Yajima

Masumi Tsuda

Hesham Nasser

Keita Mizuma

Arnon Plianchaisuk

Saori Suzuki

Keiya Uriu

Mst Monira Begum

Ryo Shimizu

Michael Jonathan

Rigel Suzuki

Takashi Kondo

Hayato Ito

Akifumi Kamiyama

Kumiko Yoshimatsu

Maya Shofa

Rina Hashimoto

Yuki Anraku

Kanako Terakado Kimura

Shunsuke Kita

Jiei Sasaki

Kaori Sasaki-Tabata

Katsumi Maenaka

Naganori Nao

Lei Wang

Yoshitaka Oda

Terumasa Ikeda

Akatsuki Saito

Keita Matsuno

Jumpei Ito

Shinya Tanaka

Kei Sato

Takao Hashiguchi

Kazuo Takayama

Takasuke Fukuhara

机构：

[1] Hokkaido University,Department of Microbiology and Immunology, Faculty of Medicine

[2] Hokkaido University,Graduate School of Medicine

[3] Hokkaido University,School of Medicine

[4] Hokkaido University,Institute for the Advancement of Higher Education

[5] Hokkaido University,Institute for Vaccine Research and Development (IVReD)

[6] Hokkaido University,One Health Research Center

[7] Hiroshima University,Graduate School of Biomedical and Health Sciences

[8] Kyoto University,Center for iPS Cell Research and Application (CiRA)

[9] Kyoto University,Laboratory of Medical Virology, Institute for Life and Medical Sciences

[10] Hokkaido University,Department of Cancer Pathology, Faculty of Medicine

[11] Hokkaido University,Institute for Chemical Reaction Design and Discovery (WPI

[12] Kumamoto University,ICReDD)

[13] Suez Canal University,Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection

[14] Hokkaido University,Department of Clinical Pathology, Faculty of Medicine

[15] The University of Tokyo,Division of Risk Analysis and Management, International Institute for Zoonosis Control

[16] The University of Tokyo,Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science

[17] Hokkaido University,Graduate School of Medicine

[18] University of Miyazaki,Institute for Genetic Medicine

[19] University of Miyazaki,Department of Veterinary Science, Faculty of Agriculture

[20] Hokkaido University,Graduate School of Medicine and Veterinary Medicine

[21] Kyushu University,Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences

[22] Hokkaido University,Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences

[23] Hokkaido University,Division of Pathogen Structure, International Institute for Zoonosis Control

[24] Hokkaido University,Global Station for Biosurfaces and Drug Discovery

[25] University of Miyazaki,Division of International Research Promotion, International Institute for Zoonosis Control

[26] Hokkaido University,Center for Animal Disease Control

[27] The University of Tokyo,International Collaboration Unit, International Institute for Zoonosis Control

[28] The University of Tokyo,International Research Center for Infectious Diseases, The Institute of Medical Science

[29] CREST,Graduate School of Frontier Sciences

[30] Japan Science and Technology Agency,International Vaccine Design Center, The Institute of Medical Science

[31] The University of Tokyo,Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection

[32] Kumamoto University,Kyoto University Immunomonitoring Center

[33] Kyoto University,Laboratory of Virus Control, Research Institute for Microbial Diseases

[34] AMED-CREST,Division of Molecular Pathobiology, International Institute for Zoonosis Control

[35] Japan Agency for Medical Research and Development (AMED),School of Medicine

[36] Osaka University,Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection

[37] Hokkaido University,undefined

[38] Kobe University,undefined

[39] Tokyo Metropolitan Institute of Public Health,undefined

[40] Tokai University School of Medicine,undefined

[41] Kyoto University,undefined

[42] Kumamoto University,undefined

来源：

Nature Communications | / 15卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.

引用

共 50 条

[21] Virological characteristics of the SARS-CoV-2 XEC variant
Kaku, Yu
Okumura, Kaho
Kawakubo, Shusuke
Uriu, Keiya
Chen, Luo
Kosugi, Yusuke
Uwamino, Yoshifumi
Begum, M. S. T. Monira
Leong, Sharee
Ikeda, Terumasa
Sadamasu, Kenji
Asakura, Hiroyuki
Nagashima, Mami
Yoshimura, Kazuhisa
Ito, Jumpei
See, Kei Sato
LANCET INFECTIOUS DISEASES, 2024, 24 (12): : e736 - e736
[22] SARS-CoV-2 Omicron variant: Characteristics and prevention
He, Xuemei
Hong, Weiqi
Pan, Xiangyu
Lu, Guangwen
Wei, Xiawei
MEDCOMM, 2021, 2 (04): : 838 - 845
[23] Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
Halfmann, Peter J.
Uraki, Ryuta
Kuroda, Makoto
Iwatsuki-Horimoto, Kiyoko
Yamayoshi, Seiya
Ito, Mutsumi
Kawaoka, Yoshihiro
EBIOMEDICINE, 2023, 93
[24] Acute thrombosis of the lower limb arteries on the background of the XBB.1.5 (“Kraken”) subvariant of omicron SARS-COV-2 — medical or surgical treatment?
Kazantsev Anton Nikolaevich
Korotkikh Alexander Vladimirovich
Unguryan Vladimir Mikhailovich
Belov Yuri Vladimirovich
Indian Journal of Thoracic and Cardiovascular Surgery, 2023, 39 : 601 - 607
[25] Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Soudani, Nadia
Bricker, Traci L.
Darling, Tamarand
Seehra, Kuljeet
Patel, Nita
Guebre-Xabier, Mimi
Smith, Gale
Davis-Gardner, Meredith
Suthar, Mehul S.
Ellebedy, Ali H.
Boon, Adrianus C. M.
JOURNAL OF VIROLOGY, 2024,
[26] Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook-2023
Akash, Shopnil
Khan, Md. Shajib
Mukerjee, Nobendu
Bibi, Shabana
INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (04) : 658 - 659
[27] Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals
Kosugi, Yusuke
Kaku, Yu
Hinay, Alfredo A., Jr.
Guo, Ziyi
Uriu, Keiya
Kihara, Minoru
Saito, Fumitake
Uwamino, Yoshifumi
Kuramochi, Jin
Shirakawa, Kotaro
Takaori-Kondo, Akifumi
Sato, Kei
LANCET INFECTIOUS DISEASES, 2024, 24 (03): : e147 - e148
[28] Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Huiberts, Anne J.
Hoeve, Christina E.
de Gier, Brechje
Cremer, Jeroen
van der Veer, Bas
de Melker, Hester E.
van de Wijgert, Janneke H. H. M.
van den Hof, Susan
Eggink, Dirk
Knoll, Mirjam J.
EUROSURVEILLANCE, 2024, 29 (10)
[29] Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies
Huo, Nan
Wu, Shipo
Wang, Yudong
Wang, Busen
Zhang, Zhe
Zhang, Jinlong
Song, Xiaohong
Hou, Lihua
Chen, Wei
EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
[30] What to know about Omicron XBB.1.5
Vogel, Lauren
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (03) : E127 - E128

← 1 2 3 4 5 →